Prescription cyclosporine eye drops, sold as Restasis and in other formulations, are not a quick-relief drop. They are meant to calm the inflammation that can stop the eyes from making enough tears, and the trials that led to approval judged results after months, not minutes. Burning when the drop goes in is the most common side effect. If you have just been prescribed them, plan on giving them time, keep using any lubricating drops your eye doctor recommends, and report burning or redness that does not settle.
What cyclosporine is and what it does in the eye
Cyclosporine is a cyclic peptide: a ring of 11 amino acids, several of them chemically modified, as its PubChem compound record and chemical name show. When given to the whole body, the label notes, it is an immune-suppressing drug. In eye drops such as Restasis it is used at 0.05%, and the Restasis prescribing information describes it as acting as a partial immunomodulator in the eye, while noting that the exact mechanism is not known. The same label reports that in people using it twice daily for up to 12 months, cyclosporine levels in the blood stayed below what the test could measure.
MedlinePlus puts it simply: the drops work by decreasing swelling in the eye to allow tear production. The National Eye Institute lists artificial tears as the most common treatment for mild dry eye and prescription drops such as cyclosporine or lifitegrast for more serious cases.
What the trials found, and how much to expect
The Restasis label describes four controlled studies in about 1,200 people with moderate to severe dry eye. At six months, an increase of 10 millimeters in wetting on the standard paper-strip (Schirmer) tear test was seen in about 15% of people using Restasis and about 5% using the inactive vehicle. The label adds that this increase was not seen in people already using anti-inflammatory eye drops or tear-duct plugs. One of the original phase 3 analyses, published in Ophthalmology in 2000, combined two six-month trials with 877 patients and reported improvements in surface staining of the eye and in some symptoms, including blurred vision and how often people needed artificial tears.
A large 2026 Cochrane review of 58 randomized trials with 10,225 participants is more cautious. It found that the 0.05% strength may improve dry eye symptoms and surface staining at three months compared with a vehicle or artificial tears, but rated that evidence low certainty, and found people on cyclosporine were probably about twice as likely to stop treatment because of side effects. That is a modest, uncertain benefit for some people, not a guaranteed fix.
Side effects and day-to-day tips from the label
- Burning: the label lists ocular burning in 17% of people in trials, with redness, discharge, watery eyes, eye pain, itching, stinging, a foreign-body feeling and blurred vision in 1% to 5%.
- Contact lenses: do not put the drops in while wearing lenses; remove them first and wait 15 minutes before putting them back in. MedlinePlus suggests talking to your doctor about lens wear if you have dry eye.
- Other drops: the label says Restasis can be used with lubricant eye drops if you leave 15 minutes between them.
- Clean technique: do not let the vial tip touch your eye or other surfaces, and discard single-use vials after use.
MedlinePlus says to tell your doctor if eye burning, itching, stinging, redness, pain, swelling, discharge or vision changes are severe or do not go away, and to get emergency care for hives, swelling of the face, throat, eyes or tongue, or shortness of breath.
Questions worth asking your eye doctor
- How long should I use these drops before we decide whether they are helping?
- Which version am I getting, and does it differ from Restasis in strength or how it feels going in?
- Should I keep using artificial tears, and how should I space them?
- Is something else, such as a medicine, screen habits or eyelid problems, contributing to my dry eye?
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the linked sources (fetched 2026-10-05 PT). Not medical advice.
Sources
- DailyMed: Restasis (cyclosporine ophthalmic emulsion) 0.05% prescribing information
- MedlinePlus (U.S. National Library of Medicine): Cyclosporine ophthalmic
- National Eye Institute: Dry eye
- Sall K, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology, 2000.
- Priyadarshini SR, et al. Topical cyclosporine A therapy for dry eye disease. Cochrane Database of Systematic Reviews, 2026.
- PubChem (NIH): Cyclosporin A, compound summary